©2012 Baishideng.
World J Transplant. Oct 24, 2012; 2(5): 74-83
Published online Oct 24, 2012. doi: 10.5500/wjt.v2.i5.74
Published online Oct 24, 2012. doi: 10.5500/wjt.v2.i5.74
Table 3 Mammalian target of rapamycin linked pathway deregulations in selected cancers
| Lung | EGFR | 32-60 |
| p-AKT | 23-50 | |
| Ras | 30 | |
| PTEN | 24 | |
| HER2 | 5 | |
| PI3K | 4 | |
| Kidney | TGF-α/TGF-β1 | 60-100 |
| VHL | 30-50 | |
| IGF-1/IGF-1R | 39-69 | |
| p-AKT | 38 | |
| PTEN | 31 | |
| TSC1/TSC2 | ||
| Breast | p-Akt | 42 |
| PTEN | 15-41 | |
| HER2 | 30-36 | |
| PI3K | 18-26 | |
| EGFR | 6 | |
| NET | TSC1/TSC2 | |
| IGF-1/IGF-1R | ||
| VHL | ||
| Colon | Ras | 50 |
| p-Akt | 46 | |
| PTEN | 35 | |
| PI3K | 20-32 | |
| EGFR | 8 | |
| HER2 | 3 |
- Citation: Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012; 2(5): 74-83
- URL: https://www.wjgnet.com/2220-3230/full/v2/i5/74.htm
- DOI: https://dx.doi.org/10.5500/wjt.v2.i5.74